Cardiometabolic and anti-ischemic therapy for cardiovascular disease and estrogen deficiency

DOI: https://doi.org/10.29296/25877305-2022-11-17
Issue: 
11
Year: 
2022

M. Khabibulina, Candidate of Medical Sciences
Ural State Medical University, Yekaterinburg

The paper gives the results of studying the impact of Mildronate therapy on the endothelial function of peripheral arteries and on the indicators of silent myocardial ischemia in women with hypertension and estradiol deficiency. Relying on the study, it may be concluded that Mildronate is well tolerated by patients and is an effective treatment: the patients report a positive effect of the drug on endothelium-dependent vascular relaxation, as well as cardiometabolic and anti-ischemic effects due to the normalization of cardiomyocyte metabolism.

Keywords: 
cardiology
cardiovascular disease
estrogen deficiency
endothelial dysfunction
silent myocardial ischemia
Mildronate



References: 
  1. Zabolevaemost' naseleniya Rossii v 2012 godu. Statisticheskie materialy. M., 2013 (in Russ.).
  2. Allen C. et al. Oxidative stress and its role in the pathogenesis of ischaemic stroke. Int J Stroke. 2009; 4 (6): 461–70. DOI: 10.1111/j.1747-4949.2009.00387.x
  3. Rumyantseva S.A., Stupin V.A. et al. Teoriya i praktika lecheniya bol'nykh s sosudistoi komorbidnost'yu. Klinicheskoe rukovodstvo. M., SPb: Mezhdunarodnaya izdatel'skaya gruppa «Med. kniga», 2013; 360 s. (in Russ.).
  4. Jaudzems K., Kuka J. et all Inhibition of carnitineacetiltransferase by mildronate, a regulator of energy metabolism. J Enzime Inhib Med Chem. 2009; 24 (6): 1269–75. DOI: 10.3109/14756360902829527
  5. Karpov R.S., Koshel'skaya O.A. et al. Klinicheskaya effektivnost' i bezopasnost' mildronata pri lechenii khronicheskoi serdechnoi nedostatochnosti u bol'nykh ishemicheskoi bolezn'yu serdtsa. Kardiologiya. 2000; 6: 69–74 (in Russ.).
  6. Nedoshivin A.O., Petrova N.N., Kutuzova A.E. et al. Effect of mildronate on life quality of patients with chronic heart failure. Ter Arkh. 1999; 71 (8): 10–2 (in Russ.).
  7. Dzerve V., Matisone D. et al. Mildronate improves the exercise tolerance in patients with stable angina, results of a long term clinical trial. Semin Cardiovasc Med. 2010; 16: 8.
  8. Smetnik V.P., Kulakova V.I. Guide to menopause. 2004; 687 р. (in Russ.).
  9. Khabibulina M.M. Cardiovascular risk in estrogen deficiency in preclimactric periods. Monograph, 2014; 193 р. (in Russ.).
  10. Chazova I.E., Smetnik V.P., Balan V.E. et al. Vedenie zhenshchin s serdechno-sosudistym riskom v peri- i postmenopauze: konsensus rossiiskikh kardiologov i ginekologov. Consilium Medicum. 2008; 10 (6): 5–18 (in Russ.).
  11. Khabibulina M.M. Structural and functional parameters of the vascular bed in premenopausal hypertensive women. Ter arkh. 2011; 83 (12): 11–5 (in Russ.).
  12. Khabibulina M.M. A method for diagnosing the development of pain-free myocardial ischemia in young women with estrogen deficiency with arterial hypertension in the late fertile period depending on intergenic interactions. Patent for the invention RUS 2601381 of 16.07.2015 (in Russ.).
  13. Khabibulina M.M. Ambulatory diagnostics of painless myocardial ischemia in premenopausal women with arterial hypertension and cardialgia. Russian Journal of Cardiology. 2011; 6 (92): 14–8 (in Russ.).
  14. Khabibulina M.M. Comparative analysis of specifics of cardiac pain syndrome and silent myocardial ischemia in women with arterial hypertension in pre-menopause depending on daily profile of blood pressure. Cardiology and cardiovascular surgery. 2011; 4 (3): 55–60 (in Russ.).
  15. Larina V., Karpenko D. The metabolic and cytoprotective orientation of meldonium in multimorbidity. Vrach. 2022; 33 (4): 56–62 (in Russ.). DOI: 10.29296/25877305-2022-04-08
  16. Shishkova V.N. Comorbidity and polypharmacy: focus on cytoprotection. Consilium Medicum. 2016; 18 (12): 73–9 (in Russ.).
  17. Shishkova V., Kapustina L. A rational approach to solving cardiometabolic problems in the therapy of comorbid patients. Vrach. 2018; 29 (11): 3–11 (in Russ.). DOI: 10.29296/25877305-2018-11-01